Supplementary Data from Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Abstract

Figure S1 shows immunoglobulin A, B, and M levels in treated patients over time Figure S2 shows investigator-assessed progression-free survival by CLL-IPI score and presence or absence of complex karyotype